March 27, 2023

Approval of “GOBIK Aqueous Suspension Syringes”,
Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib
Combined VaccineTheResearchFoundation

forMicrobial

DiseasesofOsaka

University(Headquarters: Suita City, Osaka; Director General: Koichi Yamanishi; hereafter,“BIKEN”) and Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka;
Representative Director: Hiroaki Ueno; hereafter, "MTPC") announced thattheMinistry of Health, Labour and Welfare approved on March 27 the marketing
authorization of “GOBIK Aqueous Suspension Syringes”, Adsorbed DiphtheriaPurified Pertus-sis-Tetanus-Inactivated Polio-Haemophilus type b con-jugate
Combined Vaccine（Minimum Requirements for Biological Products ）, which
they jointly developed.
This vaccine combines TETRABIK (adsorbed diphtheria-purified pertussistetanus-inactivatedpolio[Sabinstrain]

combinedvaccine)withantigenic

components of Hib. The combination vaccine for five diseases has been selected
as one of the vaccines with high development priority according to the “NationalImmunization Plan” stipulated in 2014, and GOBIK is the first vaccine approved inJapan. At present, the total number of shots of routine vaccinations required by twoyears old is twenty or more, and combination vaccines will reduce the number ofshots and the burden on infants and guardians.
BIKEN and MTPC will continue to contribute to the prevention of various infectious
diseases and the health of people around the world through the manufacture andstable supply of vaccines and therapeutic drugs.
◆Contact information
Public Relations Section, The Research Foundation for Microbial Diseases ofOsaka University

TEL: 06-6877-4802

Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group,Corporate Communications Div., Osaka Corporate Communications Dept.)
TEL: 06-6205-5119

1◆Please refer to the following URL for the infections to be prevented with pertussis,
diphtheria, tetanus, inactivated polio and Hib combined Vaccine.
https://www.cdc.gov/vaccines/parents/diseases/index.html◆About Research Foundation for Microbial Diseases of Osaka University
The BIKEN is a Specialty Bio-Pharmaceutical Organization engaged in theResearch, Development and Supply of Vaccines. Since its establishment in 1934,
BIKEN has contributed to public health by developing, manufacturing and supplying
a number of first vaccines made in Japan and providing advanced laboratory testservices. Based on its mission "Protect the precious lives of people around the world
through excellent vaccines." the BIKEN will continue to pursue the advancement ofadvanced science and unique biotechnology toward a healthy society free from
disease anxiety. https://www.biken.or.jp/english◆About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi
Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world,
founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquarteredin Doshomachi, Osaka, the birthplace of Japan’s pharmaceutical industry. MCG has
positioned health care as its strategic focus in its management policy, “Forging thefuture”. MTPC sets the MISSION of “Creating hope for all facing illness”. To that end,
MTPC is prioritizing work on “precision medicine” to provide drugs with hightreatment satisfaction by identifying patient populations with high potential forefficacy and safety, focusing on the disease areas of central nervous system andimmuno-inflammation. In addition, MTPC is working to develop “around the pillsolutions” to address specific patient concerns based on therapeutic medicine,including prevention of diseases, pre-symptomatic disease care, prevention ofaggravation and prognosis. For more information, go to https://www.mtpharma.co.jp/e/2